Physician profile
Daniel Desmond
NPI 1063892214
$1,564.73
in general payments reported to CMS, 2019-2025
27 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $109 · 2022: $267 · 2023: $374 · 2024: $563 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $206.32 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $154.73 | 2020-2025 | Xpovio |
| Astrazeneca Pharmaceuticals LP | $94.40 | 2020-2024 | |
| Celgene Corporation | $92.40 | 2022-2023 | Pomalyst |
| Gilead Sciences, INC. | $91.87 | 2023-2024 | Trodelvy |
| Incyte Corporation | $89.04 | 2020-2024 | Jakafi |
| Exelixis INC. | $86.27 | 2021-2024 | Cabometyx |
| Sobi, INC | $77.50 | 2024-2025 | |
| Morphosys, US INC. | $67.77 | 2022-2024 | Monjuvi |
| Daiichi Sankyo INC. | $62.46 | 2021-2025 | Enhertu, Vanflyta |
| Amgen INC. | $59.66 | 2020-2023 | Lumakras |
| Alexion Pharmaceuticals, INC. | $45.84 | 2022-2023 | Ultomiris |
| Recordati_rare_diseases_inc. | $45.18 | 2023-2024 | Sylvant |
| G1 Therapeutics, INC. | $43.55 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $41.30 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.89 | 2020-2021 | |
| Glaxosmithkline, LLC. | $39.50 | 2020-2021 | |
| Beigene USA, INC. | $27.26 | 2023 | Brukinsa |
| Mirati Therapeutics, INC. | $26.71 | 2024 | Krazati |
| Adc Therapeutics America, INC. | $23.95 | 2024 | |
| Abbvie INC. | $23.17 | 2024 | |
| Rigel Pharmaceuticals, INC. | $22.91 | 2023 | Rezlidhia, Tavalisse |
| Coherus Oncology, INC. | $22.69 | 2024 | |
| Stemline Therapeutics INC. | $22.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.09 | 2022 | |
| Cti Biopharma Corp. | $18.59 | 2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $18.37 | 2024 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Desmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.